Status:
COMPLETED
Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea
Lead Sponsor:
Flinders University
Conditions:
Sleep Apnea, Obstructive
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Quetiapine is medication used to treat schizophrenia and bipolar disorder. Increasingly, low doses of quetiapine are prescribed "off-label" for insomnia. Quetiapine increases sleep duration with fewer...
Eligibility Criteria
Inclusion
- Ages: 18+ (Adult, Older Adult)
- Gender: All
- Moderate or more "difficulty staying asleep" score on the Insomnia Severity Index questionnaire
- Obstructive Sleep Apnoea (OSA), Apnoea Hypopnea Index ≥ 5 events/hour
- BMI between 18.5 and 40 kg/m2
Exclusion
- Concomitant medications that interact or are contraindicated with quetiapine
- Concomitant medications known to influence breathing, sleep, arousal, or muscle physiology
- Current pregnancy or breast-feeding
- Current or recent other medical conditions likely to affect results or safety
Key Trial Info
Start Date :
May 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 4 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05303935
Start Date
May 25 2022
End Date
April 4 2023
Last Update
July 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Adelaide Institute for Sleep Health
Adelaide, South Australia, Australia, 5042